Invesco’s Aligos Therapeutics ALGS Stock Holding History

Invesco’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-474	Closed	-$26K	–	4035
2022 Q1	$26K	Sell	474 -24	-5%	-$1.92K	﹤0.01%	3973
2021 Q4	$147K	Buy	+498	New	+$182K	﹤0.01%	3844

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco's ALGS Position: Q2 2022 in Review

Invesco sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 474 shares — an estimated $26K sold.

Invesco first reported a position in ALGS in Q4 2021 and held it in 2 quarters. The position peaked at $147K in Q4 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

Invesco reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
Invesco sold 474 Aligos Therapeutics shares in Q2 2022, an estimated $26K.
Invesco first reported a position in Aligos Therapeutics in Q4 2021 and held it in 2 quarters.
Invesco's Aligos Therapeutics position peaked at $147K in Q4 2021.
59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.